Thromb Haemost 1998; 80(01): 204-205
DOI: 10.1055/s-0037-1615168
Letters to the Editor
Schattauer GmbH

Effective Treatment of Severe Bleeding due to Acquired Thrombocytopathia by Single Dose Administration of Activated Recombinant Factor VII

K. Meijer
1   Division of Thrombosis, Haemostasis and Rheology
,
E. Sieders
2   Department of Surgery, Divisions of Hepatobiliary Surgery and Liver Transplantation
,
M. J. H. Slooff
2   Department of Surgery, Divisions of Hepatobiliary Surgery and Liver Transplantation
,
J. Th. M. de Wolf
3   Department of Hematology, University Hospital Groningen, The Netherlands
,
J. van der Meer
1   Division of Thrombosis, Haemostasis and Rheology
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 23. Dezember 1998

Accepted after revision 31. März 1998

Publikationsdatum:
08. Dezember 2017 (online)

 

 
  • References

  • 1 Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa.. Thromb Haemost 1996; 75: 981-2.
  • 2 Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia.. Haemostasis 1996; 26 (Suppl. 01) 159-64.
  • 3 Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor.. Br J Haematol 1998; 99: 542-7.